Financial and competing interests disclosure
The author is a former employee, and is a current shareholder, of Bristol-Myers Squibb, which has active research programs and marketed medicines in some of the therapeutic areas covered in this article. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.